Guilia Dowgier

Dec 6, 2023 | thelancet.com | Edward Carr |Rowland Hill Street |David A. Greenwood |Guilia Dowgier

Mucosal vaccines that prevent SARS-CoV-2 infection might provide benefits beyond existing intramuscularly administered vaccines: through enhanced individual-level protection against disease, and population-level reduction of viral carriage and transmission. Secreted neutralising antibodies are most likely to be the crucial effectors for such vaccines generating a mucosal response. 1Marking U Bladh O Havervall S et al. Mucosal IgA protects against BQ.1 and BQ.1.1 infection. Lancet Infect Dis.